CAJ | 학술논문

目的评估氩氦刀经皮冷冻联合125Ⅰ粒子植入疗法治疗Ⅳ期胰腺癌的疗效.方法对2008年11月至2010年8月收治的81例Ⅳ期胰腺癌患者进行分组,其中Ⅰ组50人,原发灶与转移灶均行氩氦刀冷冻联合125Ⅰ粒子植入术治疗,Ⅱ组31入,原发灶行125Ⅰ粒子植入术治疗,转移灶行氩氦刀冷冻联合125Ⅰ粒子植入术治疗.随访2.5年,比较两组术后不良反应、中位生存期(MST)及治疗频率对MST的影响.结果 Ⅰ组和Ⅱ组患者MST分别为8个月和4个月,差异具有统计学意义(P＜0.001).Ⅰ组中接受多次和单次治疗的患者MST分别为11个月和7个月,差异有统计学意义(P=0.0389).Ⅱ组中接受多次和单次治疗的患者MST分别为4个月和3个月,差异无统计学意义(P=0.99).结论相对于原发灶行125Ⅰ粒子植入治疗、转移灶行氩氦刀冷冻联合125Ⅰ粒子植入术的Ⅳ期胰腺癌患者,原发灶与转移灶均行氩氦刀冷冻联合125Ⅰ粒子植入术且多次反复治疗的患者生存期得以延长.
목적 평고아양도경피냉동연합125Ⅰ입자식입요법치료Ⅳ기이선암적료효.방법 대2008년11월지2010년8월수치적81례Ⅳ기이선암환자진행분조,기중Ⅰ조50인,원발조여전이조균행아양도냉동연합125Ⅰ입자식입술치료,Ⅱ조31입,원발조행125Ⅰ입자식입술치료,전이조행아양도냉동연합125Ⅰ입자식입술치료.수방2.5년,비교량조술후불량반응、중위생존기(MST)급치료빈솔대MST적영향.결과 Ⅰ조화Ⅱ조환자MST분별위8개월화4개월,차이구유통계학의의(P＜0.001).Ⅰ조중접수다차화단차치료적환자MST분별위11개월화7개월,차이유통계학의의(P=0.0389).Ⅱ조중접수다차화단차치료적환자MST분별위4개월화3개월,차이무통계학의의(P=0.99).결론 상대우원발조행125Ⅰ입자식입치료、전이조행아양도냉동연합125Ⅰ입자식입술적Ⅳ기이선암환자,원발조여전이조균행아양도냉동연합125Ⅰ입자식입술차다차반복치료적환자생존기득이연장.
Objective To investigate the therapeutic effect of percutaneous cryosurgery combined with iodine-125 (125Ⅰ) seed implantation on stage Ⅳ pancreatic cancer patients.Methods Eighty-one patients with stage Ⅳ pancreatic cancer were enrolled in this study and divided into two groups according to method of treatment.Group Ⅰ consisted of 50 patients,who underwent percutaneous cryosurgery combined with 125Ⅰ seed implantation therapy for both primary and metastasis tumors.Group Ⅱ consisted of 31 patients,who underwent 125Ⅰ seed implantation therapy for primary sites and cryosurgery combined with 125Ⅰ seed implantation therapy for metastasis tumors.The patients were followed for 2.5 years,and the adverse event rates,median survival time (MST) and the effect of treatment episodes on MST were compared.Results The MST of Group Ⅰ and Ⅱwere 8 and 4 months,and the difference between the two groups was statistically significant (P ＜ 0.001).In Group Ⅰ,the MST of patients who received multiple treatments was significantly longer than those received single treatment (11 vs.7 months,P=0.0389).In group Ⅱ,the MST of patients who received multiple therapy was not significantly longer than those received single treatment (4 vs.3 months,P =0.99).Conclusions Compared with controls who receive 125Ⅰ seed implantation for primary sites and cryosurgery combined with 125Ⅰ seed implantation therapy for metastasis tumors,multiple treatment of percutaneous cryosurgery combined with 125Ⅰ seed implantation in both primary and metastasis tumors can prolong stage Ⅳ pancreatic cancer patients' survival.